397 related articles for article (PubMed ID: 28674287)
1. [A case of myasthenia gravis and myositis induced by nivolumab].
Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M
Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287
[TBL] [Abstract][Full Text] [Related]
2. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
3. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Hasegawa Y; Kawai S; Ota T; Tsukuda H; Fukuoka M
Immunotherapy; 2017 Aug; 9(9):701-707. PubMed ID: 28649876
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
6. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
Saishu Y; Yoshida T; Seino Y; Nomura T
J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
[TBL] [Abstract][Full Text] [Related]
8. [A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder].
Fukazawa R; Takezawa H; Tsuji Y; Noto Y; Banba M; Fujii A
Rinsho Shinkeigaku; 2020 Jan; 60(1):37-40. PubMed ID: 31852868
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
12. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
13. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
14. Relapsed Myasthenia Gravis after Nivolumab Treatment.
Mitsune A; Yanagisawa S; Fukuhara T; Miyauchi E; Morita M; Ono M; Tojo Y; Ichinose M
Intern Med; 2018 Jul; 57(13):1893-1897. PubMed ID: 29434145
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis induced by avelumab.
Yuen C; Fleming G; Meyers M; Soliven B; Rezania K
Immunotherapy; 2019 Oct; 11(14):1181-1185. PubMed ID: 31462152
[TBL] [Abstract][Full Text] [Related]
17. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
Chang E; Sabichi AL; Sada YH
J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
[TBL] [Abstract][Full Text] [Related]
19. Myasthenic crisis and polymyositis induced by one dose of nivolumab.
Kimura T; Fukushima S; Miyashita A; Aoi J; Jinnin M; Kosaka T; Ando Y; Matsukawa M; Inoue H; Kiyotani K; Park JH; Nakamura Y; Ihn H
Cancer Sci; 2016 Jul; 107(7):1055-8. PubMed ID: 27420474
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]